osteogenic-growth-peptide has been researched along with historphin* in 3 studies
3 other study(ies) available for osteogenic-growth-peptide and historphin
| Article | Year |
|---|---|
Regulation of endochondral ossification by osteogenic growth peptide C-terminal pentapeptide [OGP(10-14)].
In neonatal rat metatarsal organ culture, a bell-shaped dose-related curve in length of mineralized area, increases in the height of proliferative and hypertrophic zones, in the number of hypertrophic chondrocyte and in the amount of Runx2 mRNA, were revealed after treatment with OGP(10-14). We conclude that OGP(10-14) accelerates bone growth. Topics: Animals; Animals, Newborn; Bone Development; Core Binding Factor Alpha 1 Subunit; Endorphins; Growth Plate; Histones; Intercellular Signaling Peptides and Proteins; Metatarsal Bones; Mice; NIH 3T3 Cells; Oligopeptides; Organ Culture Techniques; Osteogenesis; Peptide Fragments; Rats; RNA, Messenger | 2009 |
Bone and bone marrow interactions: hematological activity of osteoblastic growth peptide (OGP)-derived carboxy-terminal pentapeptide III. Action on human megakaryocytopoiesis: focus on essential thrombocythemia.
The increase of megakaryocytes and platelets that characterizes essential thrombocythemia (ET) appears to be secondary to a deregulation of megakaryocytopoiesis. The carboxy-terminal fragment of osteogenic growth peptide (OGP10-14) promotes bone formation and hemopoiesis, while it inhibits megakaryocytopoiesis. In this paper we show that treatment with synthetic OGP10-14 (sOGP10-14) induces a significant reduction of mid and large colony-forming unit-megakaryocytes (CFU-Mk) in ET patients as well as in controls, and is associated with a significant inhibition of thrombopoietin (TPO)-primed MO-7e megakaryoblastic cells proliferation. These actions appear to be related to sOGP10-14 modulation of TGF-beta(1) synthesis and/or secretion, although a direct effect on TGF-beta receptor expression cannot be excluded. Topics: Bone Marrow; Cell Proliferation; Cytokines; Endorphins; Histones; Humans; Intercellular Signaling Peptides and Proteins; Megakaryocytes; Osteoblasts; Platelet-Derived Growth Factor; Structure-Activity Relationship; Thrombocythemia, Essential; Transforming Growth Factor beta1 | 2004 |
Bioactive pseudopeptidic analogues and cyclostereoisomers of osteogenic growth peptide C-terminal pentapeptide, OGP(10-14).
The osteogenic growth peptide (OGP) is a key factor in the mechanism of the systemic osteogenic response to local bone marrow injury. When administered in vivo, OGP stimulates osteogenesis and hematopoiesis. The C-terminal pentapeptide OGP(10-14) is the minimal amino acid sequence that retains the full OGP-like activity. Apparently, it is also the physiologic active form of OGP. Residues Tyr(10), Phe(12), Gly(13), and Gly(14) of OGP are essential for the OGP(10-14) activity. The present study explored the functional role of the peptide bonds, carboxyl and amino terminal groups, and conformational freedom in OGP(10-14). Transformations replacing the peptide bonds with surrogates such as Psi(CH(2)NH), Psi(CONMe), and Psi(CH(2)CH(2)) demonstrated that amide bonds do not contribute significantly to OGP(10-14) bioactivity. End-to-end cyclization yielded the fully bioactive cyclic pentapeptide c(Tyr-Gly-Phe-Gly-Gly). The retroinverso analogue c(Gly-Gly-phe-Gly-tyr), a cyclostereoisomer of c(Tyr-Gly-Phe-Gly-Gly), is at least as potent as the parent cyclic pentapeptide. The unique structure-activity relations revealed in this study suggest that the spatial presentation of the Tyr and Phe side chains has a major role in the productive interaction of OGP(10-14) and its truncated and conformationally constrained analogues with their cognate cellular target. Topics: Animals; Cell Division; Cell Line; Colony-Forming Units Assay; Endorphins; Female; Growth Substances; Histones; Intercellular Signaling Peptides and Proteins; Mice; Ovariectomy; Peptide Fragments; Peptides; Peptides, Cyclic; Rats; Stereoisomerism; Structure-Activity Relationship | 2002 |